Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
emtricitabine
- Development stage
- Approved
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) used in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV) infection in adults, children, and infants. It is also used as part of pre-exposure prophylaxis (PrEP) regimens to prevent HIV-1 infection in high-risk individuals when combined with other drugs such as tenofovir. Emtricitabine is a synthetic cytidine analogue that, once phosphorylated intracellularly to its active triphosphate form, inhibits HIV-1 reverse transcriptase by competing with the natural substrate deoxycytidine 5'-triphosphate. This results in premature termination of viral DNA chain elongation and prevents transcription of viral RNA into DNA, thereby reducing viral replication and load. Emtricitabine also has activity against hepatitis B virus (HBV), making it useful for patients co-infected with HIV and HBV[1][2][3][5][6]. Developed by Gilead Sciences.
- Brand names
- Emtriva
- Other names
- emtricitabine
02
Targets
Gag-Pol (HIV-1 gag-pol polyprotein)Human immunodeficiency virus type 1 reverse transcriptaseHBV Pol (Hepatitis B virus polymerase)POLE (DNA polymerase epsilon)
Beyond the preview
Go deeper on emtricitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on emtricitabine.